title: Flow cytometric DNA analysis of interleukin-2 responsive renal cell carcinoma.
abstract: Adoptive immunotherapy using interleukin-2 (IL-2) based therapy can result in marked tumor regression in some patients with metastatic renal cell carcinoma. DNA flow cytometry has not been previously studied as a predictor of outcome of this therapy. Archival paraffin embedded tumors were studied in 23 IL-2 treated patients with metastatic renal cell carcinoma. Eleven patients were complete responders (CR) and 12 were nonresponders (NR). In the CR group, 4/11 (40%) were diploid and 7/11 (60%) were aneuploid. In the NR group, 9/12 (75%) were diploid and 3/12 (25%) were aneuploid. Although there was a trend that patients with an aneuploid DNA pattern were more likely to undergo a complete response, ploidy pattern alone was not significantly predictive of response (p2 = 0.10, Fischer's exact test). When combining ploidy pattern with other variables that were predictive for complete response, such as good performance status and a higher pretreatment weight, prediction of complete response was not improved by including ploidy. This preliminary report suggests that DNA ploidy does not appear to provide any additional information concerning responsiveness to IL-2 based immunotherapy beyond that obtained by performance status and pretreatment weight in this patient population.
authors.affiliation: Department of Urology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107.
authors.forename: L G
authors.initials: LG
authors.lastname: Gomella
authors.forename: H
authors.initials: H
authors.lastname: Ehya
authors.forename: S M
authors.initials: SM
authors.lastname: Steinberg
authors.forename: M
authors.initials: M
authors.lastname: Rupp
authors.forename: M
authors.initials: M
authors.lastname: Merino
authors.forename: C
authors.initials: C
authors.lastname: Robertson
authors.forename: W M
authors.initials: WM
authors.lastname: Linehan
mesh_terms: D002292:Carcinoma, Renal Cell / Q000235:genetics* / Q000628:therapy*; D004273:DNA, Neoplasm / Q000235:genetics*; D005434:Flow Cytometry; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000235:genetics* / Q000628:therapy*; D015979:Killer Cells, Lymphokine-Activated / Q000637:transplantation; D016246:Lymphocytes, Tumor-Infiltrating / Q000637:transplantation; D011003:Ploidies; D011237:Predictive Value of Tests; D016896:Treatment Outcome
chemical_list: D004273:DNA, Neoplasm; D007376:Interleukin-2